Triazolo[1,5-a]pyrimidines as novel CDK2 inhibitors: protein structure-guided design and SAR.
Richardson, C.M., Williamson, D.S., Parratt, M.J., Borgognoni, J., Cansfield, A.D., Dokurno, P., Francis, G.L., Howes, R., Moore, J.D., Murray, J.B., Robertson, A., Surgenor, A.E., Torrance, C.J.(2006) Bioorg Med Chem Lett 16: 1353-1357
- PubMed: 16325401 
- DOI: https://doi.org/10.1016/j.bmcl.2005.11.048
- Primary Citation of Related Structures:  
2C68, 2C69, 2C6I, 2C6K, 2C6L, 2C6M, 2C6O, 2C6T - PubMed Abstract: 
Crystallographic and modelling data, in conjunction with a medicinal chemistry template-hopping approach, led to the identification of a series of novel and potent inhibitors of human cyclin-dependent kinase 2 (CDK2), with selectivity over glycogen synthase kinase-3beta (GSK-3beta). One example had a CDK2 IC(50) of 120 nM and showed selectivity over GSK-3beta of 167-fold.
Organizational Affiliation: 
Vernalis (R&D) Ltd, Granta Park, Great Abington, Cambridge CB1 6GB, UK.